1 / 10

Geonomics in Breast Cancer

Geonomics in Breast Cancer. Decoding Human Genome Luis Barreras , M.D., FACP. Breast Cancer Figures. 1 in 8 women will develop breast cancer in their lifetime 180,000 women and 2,000 men yearly will develop breast cancer Over 40,000 women and men will die from breast cancer in 2009

kimberley-peck
Download Presentation

Geonomics in Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP

  2. Breast Cancer Figures • 1 in 8 women will develop breast cancer in their lifetime • 180,000 women and 2,000 men yearly will develop breast cancer • Over 40,000 women and men will die from breast cancer in 2009 • 77% of breast cancer cases occur in women over the age of 50 • Mortality rates have decreased by 3% annually since 1990

  3. Stages of Breast Cancer • Tumor size • Nodal status • Metastasis

  4. Genetics • While genetics influence breast cancer, only 5–10% of cancers are genetically recognized • Genomic tolls focus on the genetic makeup of cancer cells • These expressions of genes can be traced to specific cancers and their behaviors

  5. BRCA 1 & 2(Breast Cancer tests for genes) • Studies reveal a 60% increase in breast and ovarian cancers, lifetime risks • Whereas in the general population, there is only 12% lifetime risk

  6. Genomic Test • Gene expression testing • % of recurrence • Benefits of treatment

  7. Marker in Breast Cancer • ER/PR • HER-2 • Proliferation • 21 – Gene Assay

  8. Response to Therapy by Gene Expression Testing

  9. Patient Case #1 • 39 year old with large tumor in breast, no lymph nodes, ER+, HER-2 neg. • Treatment prior to gene expression studies – Chemotherapy • 21 gene panel – low risk • Treatment after gene expression studies - Hormonal

  10. Patient Case #2 • 60 year old with small tumor in breast, ER +, node negative, HER-2 neg. • Treatment prior to gene expression studies – Hormonal • 21 – gene panel – high risk • Treatment after gene expression studies – Chemotherapy and Hormonal

More Related